Table of Contents Author Guidelines Submit a Manuscript
International Journal of Alzheimer’s Disease
Volume 2011 (2011), Article ID 920958, 10 pages
http://dx.doi.org/10.4061/2011/920958
Research Article

Ceramide and Related-Sphingolipid Levels Are Not Altered in Disease-Associated Brain Regions of APPSL and APPSL/PS1M146L Mouse Models of Alzheimer's Disease: Relationship with the Lack of Neurodegeneration?

Groupe de Recherche sur le Vieillissement Cérébral, GreViC EA 3808, Faculté de Médecine et de Pharmacie, 6 rue de la Milétrie, BP 199, 86034 Poitiers Cedex, France

Received 27 September 2010; Accepted 16 November 2010

Academic Editor: J. Fantini

Copyright © 2011 Laurence Barrier et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. S. Grösgen, M. O. W. Grimm, P. Frieß, and T. Hartmann, “Role of amyloid beta in lipid homeostasis,” Biochimica et Biophysica Acta, vol. 1801, no. 8, pp. 966–974, 2010. View at Publisher · View at Google Scholar · View at Scopus
  2. T. Hartmann, J. Kuchenbecker, and M. O. Grimm, “Alzheimer's disease: the lipid connection,” Journal of Neurochemistry, vol. 103, pp. 159–170, 2007. View at Publisher · View at Google Scholar · View at Scopus
  3. K. S. Vetrivel and G. Thinakaran, “Membrane rafts in Alzheimer's disease beta-amyloid production,” Biochimica et Biophysica Acta, vol. 1801, no. 8, pp. 860–867, 2010. View at Publisher · View at Google Scholar · View at Scopus
  4. Y. A. Hannun and L. M. Obeid, “The ceramide-centric universe of lipid-mediated cell regulation: stress encounters of the lipid kind,” Journal of Biological Chemistry, vol. 277, no. 29, pp. 25847–25850, 2002. View at Publisher · View at Google Scholar · View at Scopus
  5. M. Schenck, A. Carpinteiro, H. Grassmé, F. Lang, and E. Gulbins, “Ceramide: physiological and pathophysiological aspects,” Archives of Biochemistry and Biophysics, vol. 462, no. 2, pp. 171–175, 2007. View at Publisher · View at Google Scholar · View at Scopus
  6. G. Arboleda, L. C. Morales, B. Benítez, and H. Arboleda, “Regulation of ceramide-induced neuronal death: cell metabolism meets neurodegeneration,” Brain Research Reviews, vol. 59, no. 2, pp. 333–346, 2009. View at Publisher · View at Google Scholar · View at Scopus
  7. A. Morales, H. Lee, F. M. Goñi, R. Kolesnick, and J. C. Fernandez-Checa, “Sphingolipids and cell death,” Apoptosis, vol. 12, no. 5, pp. 923–939, 2007. View at Publisher · View at Google Scholar · View at Scopus
  8. B. J. Pettus, C. E. Chalfant, and Y. A. Hannun, “Ceramide in apoptosis: an overview and current perspectives,” Biochimica et Biophysica Acta, vol. 1585, no. 2-3, pp. 114–125, 2002. View at Publisher · View at Google Scholar · View at Scopus
  9. R. G. Cutler, J. Kelly, K. Storie et al., “Involvement of oxidative stress-induced abnormalities in ceramide and cholesterol metabolism in brain aging and Alzheimer's disease,” Proceedings of the National Academy of Sciences of the United States of America, vol. 101, no. 7, pp. 2070–2075, 2004. View at Publisher · View at Google Scholar · View at Scopus
  10. A. Jana and K. Pahan, “Fibrillar amyloid-β peptides kill human primary neurons via NADPH oxidase-mediated activation of neutral sphingomyelinase: implications for Alzheimer's disease,” Journal of Biological Chemistry, vol. 279, no. 49, pp. 51451–51459, 2004. View at Publisher · View at Google Scholar · View at Scopus
  11. S. Chen, J. M. Lee, C. Zeng, H. Chen, C. Y. Hsu, and J. Xu, “Amyloid beta peptide increases DP5 expression via activation of neutral sphingomyelinase and JNK in oligodendrocytes,” Journal of Neurochemistry, vol. 97, no. 3, pp. 631–640, 2006. View at Publisher · View at Google Scholar · View at Scopus
  12. M. O. W. Grimm, H. S. Grimm, A. J. Pätzold et al., “Regulation of cholesterol and sphingomyelin metabolism by amyloid-β and presenilin,” Nature Cell Biology, vol. 7, no. 11, pp. 1118–1123, 2005. View at Publisher · View at Google Scholar · View at Scopus
  13. L. Puglielli, B. C. Ellis, A. J. Saunders, and D. M. Kovacs, “Ceramide stabilizes β-site amyloid precursor protein-cleaving enzyme 1 and promotes amyloid β-peptide biogenesis,” Journal of Biological Chemistry, vol. 278, no. 22, pp. 19777–19783, 2003. View at Publisher · View at Google Scholar · View at Scopus
  14. S. Patil, J. Melrose, and C. Chan, “Involvement of astroglial ceramide in palmitic acid-induced Alzheimer-like changes in primary neurons,” European Journal of Neuroscience, vol. 26, no. 8, pp. 2131–2141, 2007. View at Publisher · View at Google Scholar · View at Scopus
  15. N. Sawamura, M. Morishima-Kawashima, H. Waki et al., “Mutant presenilin 2 transgenic mice: a large increase in the levels of Aβ342 is presumably associated with the low density membrane domain that contains decreased levels of glycerophospholipids and sphingomyelin,” Journal of Biological Chemistry, vol. 275, no. 36, pp. 27901–27908, 2000. View at Publisher · View at Google Scholar · View at Scopus
  16. I. Y. Tamboli, K. Prager, E. Barth, M. Heneka, K. Sandhoff, and J. Walter, “Inhibition of glycosphingolipid biosynthesis reduces secretion of the β-amyloid precursor protein and amyloid β-peptide,” Journal of Biological Chemistry, vol. 280, no. 30, pp. 28110–28117, 2005. View at Publisher · View at Google Scholar · View at Scopus
  17. C. G. Gottfries, I. Karlsson, and L. Svennerholm, “Membrane components separate early-onset Alzheimer's disease from senile dementia of the Alzheimer type,” International Psychogeriatrics, vol. 8, no. 3, pp. 365–372, 1996. View at Publisher · View at Google Scholar · View at Scopus
  18. X. Han, D. M. Holtzman, D. W. McKeel, J. Kelley, and J. C. Morris, “Substantial sulfatide deficiency and ceramide elevation in very early Alzheimer's disease: potential role in disease pathogenesis,” Journal of Neurochemistry, vol. 82, no. 4, pp. 809–818, 2002. View at Publisher · View at Google Scholar · View at Scopus
  19. J. W. Pettegrew, K. Panchalingam, R. L. Hamilton, and R. J. Mcclure, “Brain membrane phospholipid alterations in Alzheimer's disease,” Neurochemical Research, vol. 26, no. 7, pp. 771–782, 2001. View at Publisher · View at Google Scholar · View at Scopus
  20. H. Satoi, H. Tomimoto, R. Ohtani et al., “Astroglial expression of ceramide in Alzheimer's disease brains: a role during neuronal apoptosis,” Neuroscience, vol. 130, no. 3, pp. 657–666, 2005. View at Publisher · View at Google Scholar · View at Scopus
  21. P. Katsel, C. Li, and V. Haroutunian, “Gene expression alterations in the sphingolipid metabolism pathways during progression of dementia and Alzheimer's disease: a shift toward ceramide accumulation at the earliest recognizable stages of Alzheimer's disease?” Neurochemical Research, vol. 32, no. 4-5, pp. 845–856, 2007. View at Publisher · View at Google Scholar · View at Scopus
  22. N. Marks, M. J. Berg, M. Saito, and M. Saito, “Glucosylceramide synthase decrease in frontal cortex of Alzheimer brain correlates with abnormal increase in endogenous ceramides: consequences to morphology and viability on enzyme suppression in cultured primary neurons,” Brain Research, vol. 1191, pp. 136–147, 2008. View at Publisher · View at Google Scholar · View at Scopus
  23. C. Duyckaerts, M. C. Potier, and B. Delatour, “Alzheimer disease models and human neuropathology: similarities and differences,” Acta Neuropathologica, vol. 115, no. 1, pp. 5–38, 2008. View at Publisher · View at Google Scholar · View at Scopus
  24. G. A. Higgins and H. Jacobsen, “Transgenic mouse models of Alzheimer's disease: phenotype and application,” Behavioural Pharmacology, vol. 14, no. 5-6, pp. 419–438, 2003. View at Google Scholar · View at Scopus
  25. G. Wang, J. Silva, S. Dasgupta, and E. Bieberich, “Long-chain ceramide is elevated in presenilin 1 (PS1M146V) mouse brain and induces apoptosis in PS1 astrocytes,” Glia, vol. 56, no. 4, pp. 449–456, 2008. View at Publisher · View at Google Scholar · View at Scopus
  26. H. Cheng, Y. Zhou, D. M. Holtzman, and X. Han, “Apolipoprotein E mediates sulfatide depletion in animal models of Alzheimer's disease,” Neurobiology of Aging, vol. 31, no. 7, pp. 1188–1196, 2010. View at Publisher · View at Google Scholar · View at Scopus
  27. L. Barrier, S. Ingrand, B. Fauconneau, and G. Page, “Gender-dependent accumulation of ceramides in the cerebral cortex of the APPSL/PS1Ki mouse model of Alzheimer's disease,” Neurobiology of Aging, vol. 31, no. 11, pp. 1843–1853, 2010. View at Publisher · View at Google Scholar
  28. C. Casas, N. Sergeant, J. M. Itier et al., “Massive CA1/2 neuronal loss with intraneuronal and N-terminal truncated Aβ accumulation in a novel Alzheimer transgenic model,” American Journal of Pathology, vol. 165, no. 4, pp. 1289–1300, 2004. View at Google Scholar · View at Scopus
  29. V. Blanchard, S. Moussaoui, C. Czech et al., “Time sequence of maturation of dystrophic neurites associated with Aβ deposits in APP/PS1 transgenic mice,” Experimental Neurology, vol. 184, no. 1, pp. 247–263, 2003. View at Publisher · View at Google Scholar · View at Scopus
  30. C. Schmitz, B. P. F. Rutten, A. Pielen et al., “Hippocampal neuronal loss exceeds amyloid plaque load in a transgenic mouse model of Alzheimer’s disease,” American Journal of Pathology, vol. 164, no. 4, pp. 1495–1502, 2004. View at Google Scholar · View at Scopus
  31. S. Schäfer, O. Wirths, G. Multhaup, and T. A. Bayer, “Gender dependent APP processing in a transgenic mouse model of Alzheimer's disease,” Journal of Neural Transmission, vol. 114, no. 3, pp. 387–394, 2007. View at Publisher · View at Google Scholar · View at Scopus
  32. J. Wang, H. Tanila, J. Puoliväli, I. Kadish, and T. Van Groen, “Gender differences in the amount and deposition of amyloidβ in APPswe and PS1 double transgenic mice,” Neurobiology of Disease, vol. 14, no. 3, pp. 318–327, 2003. View at Publisher · View at Google Scholar · View at Scopus
  33. L. Barrier, S. Ingrand, M. Damjanac, A. Rioux Bilan, J. Hugon, and G. Page, “Genotype-related changes of ganglioside composition in brain regions of transgenic mouse models of Alzheimer's disease,” Neurobiology of Aging, vol. 28, no. 12, pp. 1863–1872, 2007. View at Publisher · View at Google Scholar · View at Scopus
  34. S. Ladisch and B. Gillard, “A solvent partition method for microscale ganglioside purification,” Analytical Biochemistry, vol. 146, no. 1, pp. 220–231, 1985. View at Google Scholar · View at Scopus
  35. V. V. R. Bandaru, J. Troncoso, D. Wheeler et al., “ApoE4 disrupts sterol and sphingolipid metabolism in Alzheimer's but not normal brain,” Neurobiology of Aging, vol. 30, no. 4, pp. 591–599, 2009. View at Publisher · View at Google Scholar · View at Scopus
  36. D. Z. Christensen, S. L. Kraus, A. Flohr, M. C. Cotel, O. Wirths, and T. A. Bayer, “Transient intraneuronal Aβ rather than extracellular plaque pathology correlates with neuron loss in the frontal cortex of APP/PS1KI mice,” Acta Neuropathologica, vol. 116, no. 6, pp. 647–655, 2008. View at Publisher · View at Google Scholar · View at Scopus
  37. S. Oddo, A. Caccamo, J. D. Shepherd et al., “Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Aβ and synaptic dysfunction,” Neuron, vol. 39, no. 3, pp. 409–421, 2003. View at Publisher · View at Google Scholar
  38. O. Wirths, G. Multhaup, C. Czech et al., “Intraneuronal Aβ accumulation precedes plaque formation in β-amyloid precursor protein and presenilin-1 double-transgenic mice,” Neuroscience Letters, vol. 306, no. 1-2, pp. 116–120, 2001. View at Publisher · View at Google Scholar
  39. Y. Harigaya, T. C. Saido, C. B. Eckman, C. M. Prada, M. Shoji, and S. G. Younkin, “Amyloid β protein starting pyroglutamate at position 3 is a major component of the amyloid deposits in the Alzheimer's disease brain,” Biochemical and Biophysical Research Communications, vol. 276, no. 2, pp. 422–427, 2000. View at Publisher · View at Google Scholar · View at Scopus
  40. O. Wirths, H. Breyhan, H. Cynis, S. Schilling, H. U. Demuth, and T. A. Bayer, “Intraneuronal pyroglutamate-Abeta 3-42 triggers neurodegeneration and lethal neurological deficits in a transgenic mouse model,” Acta Neuropathologica, vol. 118, no. 4, pp. 487–496, 2009. View at Publisher · View at Google Scholar · View at Scopus
  41. T. A. Bayer and O. Wirths, “Review on the APP/PS1KI mouse model: intraneuronal Aβ accumulation triggers axonopathy, neuron loss and working memory impairment,” Genes, Brain and Behavior, vol. 7, supplement 1, pp. 6–11, 2008. View at Publisher · View at Google Scholar
  42. Y. M. Kuo, T. A. Kokjohn, T. G. Beach et al., “Comparative analysis of amyloid-β chemical structure and amyloid plaque morphology of transgenic mouse and Alzheimer’s disease brains,” Journal of Biological Chemistry, vol. 276, no. 16, pp. 12991–12998, 2001. View at Publisher · View at Google Scholar · View at Scopus
  43. A. Güntert, H. Döbeli, and B. Bohrmann, “High sensitivity analysis of amyloid-beta peptide composition in amyloid deposits from human and PS2APP mouse brain,” Neuroscience, vol. 143, no. 2, pp. 461–475, 2006. View at Publisher · View at Google Scholar · View at Scopus
  44. O. Wirths, K. Thelen, H. Breyhan et al., “Decreased plasma cholesterol levels during aging in transgenic mouse models of Alzheimer's disease,” Experimental Gerontology, vol. 41, no. 2, pp. 220–224, 2006. View at Publisher · View at Google Scholar · View at Scopus
  45. D. Z. Christensen, T. A. Bayer, and O. Wirths, “Intracellular Aβ triggers neuron loss in the cholinergic system of the APP/PS1KI mouse model of Alzheimer's disease,” Neurobiology of Aging, vol. 31, no. 7, pp. 1153–1163, 2010. View at Publisher · View at Google Scholar
  46. N. Yahi, A. Aulas, and J. Fantini, “How cholesterol constrains glycolipid conformation for optimal recognition of Alzheimer's β amyloid peptide (Aβ140),” PLoS One, vol. 5, no. 2, Article ID e9079, 2010. View at Publisher · View at Google Scholar · View at Scopus
  47. S. N. Fewou, H. Büssow, N. Schaeren-Wiemers et al., “Reversal of non-hydroxy: α-hydroxy galactosylceramide ratio and unstable myelin in transgenic mice overexpressing UDP-galactose: ceramide galactosyltransferase,” Journal of Neurochemistry, vol. 94, no. 2, pp. 469–481, 2005. View at Publisher · View at Google Scholar · View at Scopus
  48. H. Hama, “Fatty acid 2-Hydroxylation in mammalian sphingolipid biology,” Biochimica et Biophysica Acta, vol. 1801, no. 4, pp. 405–414, 2010. View at Publisher · View at Google Scholar · View at Scopus
  49. J. Matsuda, M. Kido, K. Tadano-Aritomi et al., “Mutation in saposin D domain of sphingolipid activator protein gene causes urinary system defects and cerebellar Purkinje cell degeneration with accumulation of hydroxy fatty acid-containing ceramide in mouse,” Human Molecular Genetics, vol. 13, no. 21, pp. 2709–2723, 2004. View at Publisher · View at Google Scholar · View at Scopus
  50. C. Lafay-Chebassier, M. Paccalin, G. Page et al., “mTOR/p70S6k signalling alteration by Aβ exposure as well as in APP-PS1 transgenic models and in patients with Alzheimer's disease,” Journal of Neurochemistry, vol. 94, no. 1, pp. 215–225, 2005. View at Publisher · View at Google Scholar · View at Scopus